The Ewha Medical Journal
Ewha Womans University School of Medicine
Original Article

Improvement of Insulin Secretoruy Capacity According to Insulin Therapy in Non-Insulin Depentent Diabetes Mellitus

Nan Ho Kyung

Copyright ⓒ 1990. Ewha Womans University School of Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: Jul 24, 2015

Abstract

To evaluate whether the urinary and serum c-peptide is the indicator of insulin therapy in NIDDM, and whether the insulin secretery capacity improves after control of blood glucose, We measured 24 hour urinary c-peptide excretion, fasting and postprandial 2hour's serum c-peptide concentrations before and after insulin therapy in 20 patients with NIDDM.

The results were as follows ;

1) The postprandial 2 hour's serum c-peptide level was significantly lower in patients with NIDDM than normal controls, bu t fasting serum c-peptide level and 24hour urinary c-peptide excretion showed no significant difference between normal control group and patients with NIDDM

2) There was no significant difference in duration of disease, body mass index, fasting serum c-peptide level and 24 hour urinary c-peptide excretion between insulin-requiring group and non-insulin-requiring group among patients with NIDDM. But post prandial 2 hour's serum c-peptide level was significantly lower in insulin requiring group than non-insulin-requiring group before treatment.

3) After therapy with insulin, post prandial 2 hour's serum c-peptide level increased significantly in insulin requiring group, but fasting serum c-peptide and 24 hour urinary c-peptide excretion were not changed significantly after therapy with insulin comparing with the level before therapy.

Author concluded that postprandial 2 hour's serum c-peptide level was a market of insulin therapy in patients with NIDDM and insulin secretory capacity improved after controlling of blood glucose.